Report cover image

Global Blood-Based Biomarkers Market Size, By Type (Genetic Biomarkers), By Application (Cancer, Cardiovascular, Neurological Diseases), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction), By End Use, and Regional Forecasts 2024-2034

Publisher Factview Research
Published Oct 03, 2025
Length 285 Pages
SKU # FAVR20464089

Description

The global blood-based biomarkers market is valued at approximately USD 7.85 billion in 2024 and is anticipated to grow at a CAGR of 7.6% over the forecast period 2025-2034. The market is experiencing significant growth due to the rising prevalence of chronic and degenerative diseases, including cancer, cardiovascular diseases, and neurological disorders. The ability of blood-based biomarkers to offer non-invasive, cost-effective, and early disease detection solutions has positioned them as a preferred diagnostic tool in modern precision medicine.

The increasing adoption of next-generation sequencing (NGS), polymerase chain reaction (PCR), and liquid biopsy technologies has enhanced the accuracy and efficiency of biomarker-based diagnostics. Liquid biopsy-based biomarker testing is revolutionizing oncology by enabling early cancer detection through circulating tumor DNA (ctDNA) analysis. Moreover, advancements in AI-driven biomarker analysis are optimizing disease prediction models and personalized treatment plans, improving patient outcomes. Strategic industry partnerships, such as the collaboration between ADx NeuroSciences and Alamar Biosciences for high-sensitivity neurodegenerative biomarkers, further fuel market expansion.

Despite its strong growth trajectory, regulatory and reimbursement challenges present hurdles in widespread biomarker adoption. Limited reimbursement frameworks in healthcare systems, particularly for emerging biomarker-driven diagnostics, can impact accessibility and affordability. However, continued government investments in precision medicine, rising awareness of preventive diagnostics, and improving regulatory pathways for biomarker approval are expected to mitigate these barriers over time.

North America holds the largest market share, attributed to strong R&D investments, an established healthcare infrastructure, and increasing adoption of biomarker-based diagnostics. The U.S. market, in particular, is witnessing a surge in approvals for innovative biomarker-based tests, such as Labcorp’s pTau217 blood biomarker for Alzheimer's disease. The Asia Pacific region is projected to experience the fastest growth, driven by expanding healthcare access, rising chronic disease prevalence, and growing biomarker research investments in China, India, and Japan.

Major Market Players Included in This Report:
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cleveland Diagnostics, Inc.
  • BIOMÉRIEUX
  • Sysmex Corporation
  • Exact Sciences Corporation
  • Quanterix Corporation
  • Guardant Health, Inc.
  • Menarini Silicon Biosystems
  • Sunbird Bio
  • QIAGEN N.V.
  • Harbinger Health
The Detailed Segments and Sub-Segments of the Market are Explained Below:

By Type:
  • Genetic Biomarkers
  • Protein Biomarkers
  • Metabolic Biomarkers
  • Cell-Based Biomarkers
  • Epigenetic Biomarkers
By Application:
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
By Technology:
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunoassays
  • Mass Spectrometry
  • Others
By End Use:
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Others
By Region:

North America:
  • U.S.
  • Canada
  • Mexico
Europe:
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
Asia Pacific:
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
Latin America:
  • Brazil
  • Argentina
Middle East & Africa:
  • Saudi Arabia
  • UAE
  • South Africa
  • Kuwait
Years Considered for the Study Are as Follows:
  • Historical Year – 2022, 2024
  • Base Year – 2024
  • Forecast Period – 2024 to 2034
Key Takeaways:
  • Market Estimates & Forecast for 10 years (2022-2034)
  • Annualized Revenue and Regional Level Analysis for Each Market Segment
  • Detailed Geographical Landscape Analysis with Country-Level Market Insights
  • Competitive Landscape, Market Share Analysis & Key Business Strategies
  • Demand-Supply Analysis & Future Market Outlook
  • Key Investment Opportunities & Emerging Trends in the Facial Tissues Industry
  • Regulatory Landscape & Impact on Market Growth

Table of Contents

285 Pages
Chapter 1. Global Blood-Based Biomarkers Market Executive Summary
1.1. Global Blood-Based Biomarkers Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Application
1.3.3. By Technology
1.3.4. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6 Industry Metrics
1.7 Investment Analysis
1.8 Investment Rationale
1.9. Analyst Recommendation & Conclusion
Chapter 2. Global Blood-Based Biomarkers Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Blood-Based Biomarkers Market Dynamics
3.1. Market Drivers
3.1.1. Rising incidence of cancer, cardiovascular, and neurological diseases
3.1.2. Growing adoption of liquid biopsy and non-invasive diagnostics
3.1.3. Technological advancements in biomarker-based detection methods
3.2. Market Challenges
3.2.1. Limited reimbursement policies for biomarker-driven diagnostics
3.2.2. Stringent regulatory requirements affecting approval timelines
3.3. Market Opportunities
3.3.1. Increasing R&D investments in precision medicine and personalized healthcare
3.3.2. Expanding role of AI and machine learning in biomarker discovery
3.3.3. Growth in strategic collaborations and industry partnerships
Chapter 4. Global Blood-Based Biomarkers Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Blood-Based Biomarkers Market Size & Forecasts by Type (2024-2034)
5.1. Segment Dashboard
5.2. Global Blood-Based Biomarkers Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Genetic Biomarkers
5.2.2. Protein Biomarkers
5.2.3. Metabolic Biomarkers
5.2.4. Cell-Based Biomarkers
5.2.5. Epigenetic Biomarkers
Chapter 6. Global Blood-Based Biomarkers Market Size & Forecasts by Application (2024-2034)
6.1. Segment Dashboard
6.2. Global Blood-Based Biomarkers Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Cancer
6.2.2. Cardiovascular Diseases
6.2.3. Neurological Diseases
6.2.4. Immunological Diseases
6.2.5. Others
Chapter 7. Global Blood-Based Biomarkers Market Size & Forecasts by Technology (2024-2034)
7.1. Segment Dashboard
7.2. Global Blood-Based Biomarkers Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Next-Generation Sequencing
7.2.2. Polymerase Chain Reaction
7.2.3. Immunoassays
7.2.4. Mass Spectrometry
7.2.5. Others
Chapter 8. Global Blood-Based Biomarkers Market Size & Forecasts by End Use (2024-2034)
8.1. Segment Dashboard
8.2. Global Blood-Based Biomarkers Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospitals & Clinics
8.2.2. Diagnostic Laboratories
8.2.3. Research & Academic Institutes
8.2.4. Others
Chapter 9. Global Blood-Based Biomarkers Market Size & Forecasts by Region (2024-2034)
9.1. North America
• U.S.
• Canada
• Mexico
9.2. Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway
9.3. Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
9.4. Latin America
• Brazil
• Argentina
9.5. Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Kuwait
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Abbott
10.1.2. F. Hoffmann-La Roche Ltd.
10.1.3. Thermo Fisher Scientific, Inc.
10.2. Top Market Strategies
10.3. Company Profiles
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Cleveland Diagnostics, Inc.
• BIOMÉRIEUX
• Sysmex Corporation
• Exact Sciences Corporation
• Quanterix Corporation
• Guardant Health, Inc.
• Menarini Silicon Biosystems
• Sunbird Bio
• QIAGEN N.V.
• Harbinger Health
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us